Astellas' sales expectations are up for Padcev, down for Veozah

Less than two months after the FDA approved the combination treatment of Astellas and Pfizer’s Padcev and Merck’s Keytruda in first-line bladder cancer, the Japanese company has raised its peak sales potential for its antibody-drug conjugate by 100 billion Japanese yen ($673 million).